US 12,343,326 B2
Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
Blake Mandell, Brooklyn, NY (US); Martin Stogniew, Lakewood Ranch, FL (US); and Jennifer Louise Schmidt, Garden City, NY (US)
Assigned to TRANSCEND THERAPEUTICS, INC., New York, NY (US)
Filed by Transcend Therapeutics, Inc., New York, NY (US)
Filed on Jul. 25, 2024, as Appl. No. 18/784,243.
Application 18/784,243 is a continuation of application No. PCT/US2024/032615, filed on Jun. 5, 2024.
Application 18/784,243 is a continuation of application No. 18/215,547, filed on Jun. 28, 2023, granted, now 12,059,402.
Application 18/784,243 is a continuation of application No. PCT/US2023/012196, filed on Feb. 2, 2023.
Application 18/215,547 is a continuation of application No. 17/887,962, filed on Aug. 15, 2022, granted, now 11,707,446, issued on Jul. 25, 2023.
Application PCT/US2023/012196 is a continuation in part of application No. PCT/US2022/074369, filed on Aug. 1, 2022.
Application 17/887,962 is a continuation of application No. PCT/US2022/074369, filed on Aug. 1, 2022.
Claims priority of provisional application 63/649,653, filed on May 20, 2024.
Claims priority of provisional application 63/553,788, filed on Feb. 15, 2024.
Claims priority of provisional application 63/607,702, filed on Dec. 8, 2023.
Claims priority of provisional application 63/605,729, filed on Dec. 4, 2023.
Claims priority of provisional application 63/602,904, filed on Nov. 27, 2023.
Claims priority of provisional application 63/471,412, filed on Jun. 6, 2023.
Claims priority of provisional application 63/437,000, filed on Jan. 4, 2023.
Claims priority of provisional application 63/328,343, filed on Apr. 7, 2022.
Claims priority of provisional application 63/325,757, filed on Mar. 31, 2022.
Claims priority of provisional application 63/255,706, filed on Oct. 14, 2021.
Claims priority of provisional application 63/240,113, filed on Sep. 2, 2021.
Claims priority of provisional application 63/230,237, filed on Aug. 6, 2021.
Prior Publication US 2025/0009711 A1, Jan. 9, 2025
Int. Cl. A61K 31/36 (2006.01); A61K 45/06 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/36 (2013.01) [A61K 45/06 (2013.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01)] 5 Claims
 
1. A method of treating and/or alleviating pain in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising methylone (3,4-methylenedioxy-N-methylcathinone) or a pharmaceutically acceptable salt thereof, and/or an enantiomer thereof, and/or an isotopologue thereof, and/or an isotopomer thereof, and/or a solvate thereof, and/or a prodrug thereof, and/or a polymorph thereof.